Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients

Not yet recruiting

• Conditions: Pneumocystis; Immunocompromised Patients

• Registration Number: NCT06890078
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

Evaluate new diagnostic methods using qPCR on non-invasive samples, compared with reference techniques for the positive diagnosis of pneumocystis (PcP) in immunocompromised patients

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-03
• Study First Submitted: 2025-03-17
• Study First Submitted QC: 2025-03-17
• Last Update Submitted: 2025-03-17
• Study First Posted: 2025-03-21
• Last Update Posted: 2025-03-21
• Study Start: 2025-04-15
• Primary Completion: 2027-05-01
• Study Completion: 2027-05-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

• adult patients with suspected pneumocystis
• with an indication for bronchial fibroscopy for BAL or induced sputum
• no opposition to the research from the adult patient or his or her next of kin research for patients unable to express their non-opposition

Exclusion Criteria

• Pneumocystis treated for more than 72 hours
• pregnancy/breast-feeding
• adult patients deprived of liberty, protected

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pearson correlation coefficient	At inclusion	Pearson correlation coefficient between the fungal load obtained by PCR on nasopharyngeal swabs nasopharyngeal swab and buccal lavage and that obtained by reference samples (induced sputum or BAL) in patients with confirmed PcP.

Secondary Outcome Measures

Name	Time	Method
Fungal load by qPCR	At inclusion	Quantitative fungal load results obtained by qPCR on nasopharyngeal swab, mouthwash, induced sputum, BAL
Fungal load by serum PCR	At inclusion	Quantitative fungal load results obtained by serum PCR
Beta D glucan blood levels	At inclusion